Urology Conferences


Study: 177Lutetium-PSMA-617 After 223Radium for mCRPC Safe, Effective

Treatment with 177lutetium-PSMA-617 (177Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223radium (223Ra), according to study findings presented at the European Society for Medical Oncology’s 2022 Congress (ESMO 2022) in Paris, France. In a study of 133 patients who participated in the RALU trial, Kambiz Rahbar,…

Next post in International Continence Society